Case number 2020-1407
Takeda Pharmaceuticals U.S.A. v. Mylan Pharmaceuticals Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | TAKEDA PHARMACEUTICALS U.S.A. v. MYLAN PHARMACEUTICALS INC. [OPINION] [precedential] (0) |
| Sep 8, 2020 | 99 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [720031] [20-1407, 20-1417] [JAB] [Entered: 09/08/2020 11:37 AM] (1) |
| Jul 31, 2020 | 98 | NOTICE OF WITHDRAWAL OF APPEARANCE OF SHYAMKRISHNA PALAIYANUR for Appellee Mylan Pharmaceuticals Inc.. Service: 07/31/2020 by email. [711665] [20-1407] [Shyamkrishna Palaiyanur] [Entered: 07/31/2020 03:33 PM] (2) |
| Jul 31, 2020 | 97 | JUDGMENT. AFFIRMED. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [711532] [20-1407, 20-1417] [JAB] [Entered: 07/31/2020 09:57 AM] (1) |
| Jul 31, 2020 | 96 | OPINION filed for the court by Prost, Chief Judge; Newman, Circuit Judge and Hughes, Circuit Judge. Dissenting opinion filed by Circuit Judge Newman. Precedential Opinion. [711531] [20-1407, 20-1417] [JAB] [Entered: 07/31/2020 09:56 AM] (24) |
| Jun 10, 2020 | 95 | RESPONSE of Appellee Mylan Pharmaceuticals Inc. to the supplemental authority [94] filed by Appellant Takeda Pharmaceuticals U.S.A., Inc.. Service: 06/10/2020 by email. [700401] [20-1407] [Michael Sommer] [Entered: 06/10/2020 05:12 PM] (2) |
| Jun 9, 2020 | 94 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellant Takeda Pharmaceuticals U.S.A., Inc.. Service: 06/09/2020 by email. [700061] [20-1407] [Porter Fleming] [Entered: 06/09/2020 12:13 PM] (13) |
| Jun 8, 2020 | 93 | Submitted after ORAL ARGUMENT by Mr. Porter F. Fleming for Takeda Pharmaceuticals U.S.A., Inc. and Mr. Michael S. Sommer for Mylan Pharmaceuticals Inc. Panel: Judge: Prost , Judge: Newman , Judge: Hughes. [699772] [JCP] [Entered: 06/08/2020 10:24 AM] (0) |
| Jun 5, 2020 | 92 | ORDER filed consolidating appeals for the purpose of oral argument. Each side will have a total of 20 minutes for the consolidated argument. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [699666] [20-1407, 20-1545] [JAB] [Entered: 06/05/2020 04:06 PM] (2) |
| May 19, 2020 | 91 | Clerk's letter to Appellant Takeda Pharmaceuticals U.S.A., Inc. and Appellee Mylan Pharmaceuticals Inc. regarding Telephonic Argument Orientation. Service as of this date by the Clerk of Court. [695649] [JAB] [Entered: 05/19/2020 12:41 PM] (0) |
| May 12, 2020 | 90 | ORDER filed. The court will conduct arguments in these cases by telephone at the originally scheduled date and time in lieu of in-person appearance. The Clerk's Office will provide additional instructions to counsel at least one week ahead of argument. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [693875] [20-1407, 20-1545] [JAB] [Entered: 05/12/2020 11:20 AM] (2) |
| Apr 24, 2020 | 89 | RESPONSE of Appellee Mylan Pharmaceuticals Inc. to the supplemental authority [88] filed by Appellant Takeda Pharmaceuticals U.S.A., Inc.. Service: 04/24/2020 by email. [689930] [20-1407] [Michael Sommer] [Entered: 04/24/2020 05:13 PM] (2) |
| Apr 23, 2020 | 88 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellant Takeda Pharmaceuticals U.S.A., Inc.. Service: 04/23/2020 by email. [689538] [20-1407] [Porter Fleming] [Entered: 04/23/2020 02:37 PM] (9) |
| Apr 14, 2020 | 87 | 6 paper copies of the Amicus Brief [67] received from Amici Curiae Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA, Inc. [687154] [CJF] [Entered: 04/15/2020 01:44 PM] (0) |
| Apr 13, 2020 | 86 | 6 paper copies of the Corrected Confidential Appendix (Vol. I - II) [72] received from Appellant Takeda Pharmaceuticals U.S.A., Inc. [686765] [CJF] [Entered: 04/14/2020 11:39 AM] (0) |
| Apr 13, 2020 | 85 | 6 paper copies of the Corrected Reply Brief [56] received from Appellant Takeda Pharmaceuticals U.S.A., Inc. [686762] [CJF] [Entered: 04/14/2020 11:37 AM] (0) |
| Apr 13, 2020 | 84 | 6 paper copies of the Opening Brief [35] received from Appellant Takeda Pharmaceuticals U.S.A., Inc. [686760] [CJF] [Entered: 04/14/2020 11:37 AM] (0) |
| Apr 13, 2020 | 81 | Response to notice of oral argument from the Appellee Mylan Pharmaceuticals Inc.. [686291] [20-1407] [Michael Sommer] [Entered: 04/13/2020 10:25 AM] (3) |
| Apr 10, 2020 | 80 | Note to file: 20-1545 (COMP COMPANION started 04/10/2020) with 20-1407. These cases shall be considered companion cases and assigned to the same merits panel for oral argument. [686037] [20-1407, 20-1545] [JAL] [Entered: 04/10/2020 02:16 PM] (0) |
| Apr 10, 2020 | 79 | Response to notice of oral argument from the Appellant Takeda Pharmaceuticals U.S.A., Inc.. [686034] [20-1407] [Edgar Haug] [Entered: 04/10/2020 02:11 PM] (2) |
| Apr 10, 2020 | 78 | NOTICE OF ORAL ARGUMENT. Panel: 2006N. Case scheduled June 8, 2020 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 201. Response to Notice of Oral Argument due: 05/15/2020. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [685976] [JAB] [Entered: 04/10/2020 12:02 PM] (2) |
| Apr 9, 2020 | 83 | 6 paper copies of the Opening Response Brief [47] received from Appellee Mylan Pharmaceuticals Inc. [686498] [CJF] [Entered: 04/13/2020 04:11 PM] (0) |
| Apr 9, 2020 | 82 | 6 paper copies of the Corrected Opening Response Brief [70] received from Appellee Mylan Pharmaceuticals Inc. [686396] [CJF] [Entered: 04/13/2020 01:41 PM] (0) |
| Apr 9, 2020 | 77 | Notice from Appellant Takeda Pharmaceuticals U.S.A., Inc. regarding conflicts with oral argument. None. Service: 04/09/2020 by email. [685762] [20-1407] [Porter Fleming] [Entered: 04/09/2020 06:01 PM] (0) |
| Apr 9, 2020 | 76 | Notice from Appellee Mylan Pharmaceuticals Inc. regarding conflicts with oral argument. None. Service: 04/09/2020 by email. [685732] [20-1407] [Michael Sommer] [Entered: 04/09/2020 04:33 PM] (2) |
| Apr 7, 2020 | 75 | Outstanding paper copies of all briefs and appendices must be submitted on or before 04/17/2020. See Administrative Order No. 20-01 (Mar. 20, 2020). [684903] [MJL] [Entered: 04/07/2020 02:58 PM] (0) |
| Apr 7, 2020 | 74 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [684895] [MJL] [Entered: 04/07/2020 02:53 PM] (1) |
| Apr 7, 2020 | 73 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: The joint appendix ([71], [72]), did not indicate on the cover that it was corrected. CORRECTION: Pursuant to the court's electronic filing procedures, corrected filings must so indicate on the cover. Please ensure future corrected filings comply with this requirement. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [684890] [MJL] [Entered: 04/07/2020 02:46 PM] (0) |
| Apr 3, 2020 | 72 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL APPENDIX FILED for Takeda Pharmaceuticals U.S.A., Inc. Number of Pages: 975. Service: 04/03/2020 by email. [684183]--[Edited 04/07/2020 by MJL - compliance review complete] [Edgar Haug] [Entered: 04/03/2020 09:49 PM] (0) |
| Apr 3, 2020 | 71 | MODIFIED ENTRY: CORRECTED APPENDIX FILED for Takeda Pharmaceuticals U.S.A., Inc. Number of Pages: 969. Service: 04/03/2020 by email. [684182]--[Edited 04/07/2020 by MJL - compliance review complete] [Edgar Haug] [Entered: 04/03/2020 09:45 PM] (969) |
| Apr 3, 2020 | 70 | MODIFIED ENTRY: CORRECTED BRIEF FILED for Mylan Pharmaceuticals Inc. Number of Pages: 18. Service: 04/03/2020 by email. [684107]--[Edited 04/07/2020 by MJL - compliance review complete] [Michael Sommer] [Entered: 04/03/2020 03:49 PM] (28) |
| Apr 2, 2020 | 69 | Entry of appearance for Stu A. Williams as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 04/02/2020 by email. [683887] [20-1407] [Stu Williams] [Entered: 04/02/2020 10:08 PM] (1) |
| Mar 30, 2020 | 68 | NOTICE OF NON-COMPLIANCE: The submissions of Takeda Pharmaceuticals U.S.A., Inc., Joint Appendix ([61], [63]), and Mylan Pharmaceuticals Inc., Response Brief [65], are not in compliance with the rules of this court (see attached). Compliant documents due 04/06/2020. Service as of this date by the Clerk of Court. [682726] [MJL] [Entered: 03/30/2020 02:11 PM] (2) |
| Mar 27, 2020 | 66 | Amended Entry of appearance for Charles B. Klein as principal counsel for Amici Curiae Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA, Inc.. Service: 03/27/2020 by email. [682492] [20-1407] [Charles Klein] [Entered: 03/27/2020 04:22 PM] (2) |
| Mar 26, 2020 | 65 | MODIFIED ENTRY: FILED from Mylan Pharmaceuticals Inc. Title: RESPONSE BRIEF. Service: 03/26/2020 by email. [682189]--[Edited 03/30/2020 by MJL to correct filing event]. This brief is non-compliant. See Doc. No. [68]. [Michael Sommer] [Entered: 03/26/2020 06:34 PM] (28) |
| Mar 26, 2020 | 67 | AMICUS BRIEF FILED for Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA, Inc. Pages: 13. Service: 02/26/2020 by email. [682723] [MJL] [Entered: 03/30/2020 01:51 PM] (21) |
| Mar 26, 2020 | 64 | ORDER filed granting [39] Hikma's motion. The brief amici curiae is accepted for filing. Mylan's request for leave to file a response [45] is granted. Mylan is directed to file separately the proposed response that it attached to its request for leave to file that response. Service as of this date by the Clerk of Court. [682157] [LMS] [Entered: 03/26/2020 04:18 PM] (2) |
| Mar 23, 2020 | 63 | FILED from Appellant Takeda Pharmaceuticals U.S.A., Inc.. Title: CONFIDENTIAL APPENDIX. Service: 03/23/2020 by email. [681168] [20-1407]. This appendix is non-compliant. See Doc. No. [68]. [Edgar Haug] [Entered: 03/23/2020 07:32 PM] (0) |
| Mar 23, 2020 | 62 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellant Takeda Pharmaceuticals U.S.A., Inc.. Service: 03/23/2020 by email. [681166] [20-1407] [Edgar Haug] [Entered: 03/23/2020 07:25 PM] (2) |
| Mar 23, 2020 | 61 | FILED from Appellant Takeda Pharmaceuticals U.S.A., Inc.. Title: APPENDIX. Service: 03/23/2020 by email. [681163] [20-1407]. This appendix is non-compliant. See Doc. No. [68]. [Edgar Haug] [Entered: 03/23/2020 07:18 PM] (969) |
| Mar 23, 2020 | 60 | CORRECTED ORDER: correcting court order [59]; reason(s): typographical changes. Service as of this date by the Clerk of Court. [681124] [LMS] [Entered: 03/23/2020 05:19 PM] (4) |
| Mar 23, 2020 | 59 | ORDER filed denying [6] motion for an injunction pending appeal, and the interim injunction granted in the court's January 29, 2020 order is lifted. Mylan’s motion to modify the court's January 29, 2020 order [49] is denied. (Per Curiam). Service as of this date by the Clerk of Court. [681093] [LMS] [Entered: 03/23/2020 04:25 PM] (0) |
| Mar 23, 2020 | 58 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellant Takeda Pharmaceuticals U.S.A., Inc. and Appellee Mylan Pharmaceuticals Inc.. Service: 03/23/2020 by email. [681067] [20-1407] [Edgar Haug] [Entered: 03/23/2020 03:33 PM] (3) |
| Mar 20, 2020 | 57 | REPLY of Appellee Mylan Pharmaceuticals Inc. to response [53]. Service: 03/20/2020 by email. [680713] [20-1407] [Michael Sommer] [Entered: 03/20/2020 05:09 PM] (19) |
| Mar 18, 2020 | 56 | MODIFIED ENTRY: CORRECTED REPLY BRIEF FILED for Takeda Pharmaceuticals U.S.A., Inc. Number of Pages: 29. Service: 03/18/2020 by email. [680099]--[Edited 03/19/2020 by MJL - compliance review complete] [Edgar Haug] [Entered: 03/18/2020 09:38 PM] (39) |
| Mar 18, 2020 | 55 | Notice of Correction to Doc No. [54] for Appellant Takeda Pharmaceuticals U.S.A., Inc.. Service: 03/18/2020 by email. [680098] [20-1407] [Edgar Haug] [Entered: 03/18/2020 09:34 PM] (2) |
| Mar 18, 2020 | 54 | FILED from Appellant Takeda Pharmaceuticals U.S.A., Inc.. Title: REPLY BRIEF. Service: 03/18/2020 by email. [680067] [20-1407]. This brief has been corrected. See Doc. No. [56]. [Edgar Haug] [Entered: 03/18/2020 05:49 PM] (38) |
| Mar 18, 2020 | 53 | RESPONSE of Appellant Takeda Pharmaceuticals U.S.A., Inc. to the motion for other relief [49] filed by Appellee Mylan Pharmaceuticals Inc.. Service: 03/18/2020 by email. [680066] [20-1407] [Edgar Haug] [Entered: 03/18/2020 05:43 PM] (26) |
| Mar 17, 2020 | 52 | Letter from Appellee Mylan Pharmaceuticals Inc. Letter from Mylan Pharmaceuticals Inc. regarding a recent filing submitted by Alkem Laboratories Ltd. and Ascend Laboratories LLC in a related matter. Service: 03/17/2020 by email. [679473] [20-1407] [Michael Sommer] [Entered: 03/17/2020 12:54 PM] (3) |
| Mar 16, 2020 | 51 | ORDER Takeda is directed to respond to the motion [49] no later than March 18, 2020. Service as of this date by the Clerk of Court. [679209] [LMS] [Entered: 03/16/2020 03:56 PM] (2) |
| Mar 13, 2020 | 50 | Confidential EMERGENCY MOTION OF DEFENDANT-APPELLEE FOR MODIFICATION OF STATUS QUO ORDER AND FOR BOND DURING THE PENDENCY OF THE STATUS QUO ORDER filed by Appellee Mylan Pharmaceuticals Inc. corresponding to Doc. No. [49]. Service: 03/13/2020 by email. [678831] [20-1407] [Michael Sommer] [Entered: 03/13/2020 11:34 PM] (0) |
| Mar 13, 2020 | 49 | MOTION of Appellee Mylan Pharmaceuticals Inc. EMERGENCY MOTION OF DEFENDANT-APPELLEE FOR MODIFICATION OF STATUS QUO ORDER AND FOR BOND DURING THE PENDENCY OF THE STATUS QUO ORDER [Consent: opposed]. Service: 03/13/2020 by email. [678830] [20-1407] [Michael Sommer] [Entered: 03/13/2020 11:28 PM] (55) |
| Mar 12, 2020 | 48 | ORDER filed. The court's January 29, 2020 order in Appeal Nos. 2020-1407, -1417, leaving in place the district court's order for Mylan Pharmaceuticals Inc. to “maintain the status quo,” remains in effect. (Per Curiam). Service as of this date by the Clerk of Court. [678370] [20-1407, 20-1545] [LMS] [Entered: 03/12/2020 04:17 PM] (2) |
| Mar 11, 2020 | 47 | MODIFIED ENTRY: BRIEF FILED for Mylan Pharmaceuticals Inc.. Number of Pages: 63. Service: 03/11/2020 by email. [678071]--[Edited 03/17/2020 by MJL - compliance review complete] [Michael Sommer] [Entered: 03/11/2020 10:51 PM] (78) |
| Mar 6, 2020 | 46 | MODIFIED ENTRY: REPLY of Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA, Inc. to response [45]. Service: 03/06/2020 by email. [677071]--[Edited 03/09/2020 by MJL - to correct filing event] [Charles Klein] [Entered: 03/06/2020 06:35 PM] (13) |
| Mar 4, 2020 | 45 | MODIFIED ENTRY: RESPONSE of Mylan Pharmaceuticals Inc. to the motion for leave to file an amicus curiae brief [39] filed by Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA, Inc. in 20-1407 with MOTION for leave to file a response brief. Service: 03/04/2020 by email [676425]--[Edited 03/09/2020 by MJL to correct event] [Michael Sommer] [Entered: 03/04/2020 11:34 PM] (51) |
| Feb 28, 2020 | 44 | ORDER filed. Any opposition to the motion [39] shall be filed no later than five days from the date of issuance of this order. Any reply is due no later than two days from the filing of the response. Service as of this date by the Clerk of Court. [675130] [NL] [Entered: 02/28/2020 12:08 PM] (2) |
| Feb 28, 2020 | 43 | Letter from Appellee Mylan Pharmaceuticals Inc. regarding deadline for Defendant-Appellee Mylan Pharmaceuticals Inc.'s opposition to Hikma Pharmaceuticals U.S.A., Inc. and Hikma Pharmaceuticals International Limited's Motion for Leave to File a Brief as Amici Curiae. Dkt. No. 39.. Service: 02/28/2020 by email. [675070] [20-1407] [Michael Sommer] [Entered: 02/28/2020 10:12 AM] (2) |
| Feb 27, 2020 | 42 | Certificate of Interest for Amici Curiae Hikma Pharmaceuticals USA, Inc. and Hikma Pharmaceuticals International Limited. Service: 02/27/2020 by email. [674940] [20-1407] [Charles Klein] [Entered: 02/27/2020 03:56 PM] (4) |
| Feb 27, 2020 | 41 | Notice to counsel for Amici Curiae Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA, Inc.: The record of this case indicates that the Certificate of Interest has not been filed. Service as of this date by the Clerk of Court. [674835] [JAL] [Entered: 02/27/2020 01:44 PM] (0) |
| Feb 26, 2020 | 40 | AMICUS BRIEF FILED for Amici Curiae Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA, Inc. Pages: 7. Service: 02/03/2020 by email. [674834] [Accepted pursuant to order [37]] [JAL] [Entered: 02/27/2020 01:43 PM] (21) |
| Feb 26, 2020 | 39 | MOTION of Amici Curiae Hikma Pharmaceuticals USA, Inc. and Hikma Pharmaceuticals International Limited for leave to file an amicus curiae brief [Consent: opposed]. Service: 02/26/2020 by email. [674587] [20-1407] [Charles Klein] [Entered: 02/26/2020 07:11 PM] (31) |
| Feb 26, 2020 | 38 | Letter from Appellant Takeda Pharmaceuticals U.S.A., Inc. Response to ECF No. 36. Service: 02/26/2020 by email. [674537] [20-1407] [Porter Fleming] [Entered: 02/26/2020 04:36 PM] (5) |
| Feb 26, 2020 | 37 | ORDER filed granting motion [18] for leave to file a brief amici curiae. The brief is accepted for filing. (Per Curiam). Service as of this date by the Clerk of Court. [674408] [LMS] [Entered: 02/26/2020 02:16 PM] (2) |
| Feb 26, 2020 | 36 | Letter from Appellee Mylan Pharmaceuticals Inc. Letter regarding development relevant to ECF No. 6, Takeda's Emergency Motion for Injunction Pending Appeal. Service: 02/26/2020 by email. [674368] [20-1407] [Michael Sommer] [Entered: 02/26/2020 01:39 PM] (7) |
| Feb 19, 2020 | 35 | MODIFIED ENTRY: OPENING BRIEF FILED for Appellant Takeda Pharmaceuticals U.S.A., Inc.. Number of Pages: 40. Service: 02/19/2020 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [672635] --[Edited 02/21/2020 by TAM - compliance review complete] [Edgar Haug] [Entered: 02/19/2020 07:12 PM] (59) |
| Feb 19, 2020 | 34 | Note to file: The following cases are associated:20-1407 (Lead) with 20-1417 (Member Case). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [672567] [20-1407, 20-1417] [TAM] [Entered: 02/19/2020 04:33 PM] (0) |
| Feb 19, 2020 | 33 | ORDER consolidating the appeals. The revised official caption is reflected above. One set of briefs should be filed for the two appeals. Takeda's opening brief remains due no later than February 19, 2020. Service as of this date by the Clerk of Court. [672520] [20-1407, 20-1417] [LMS] [Entered: 02/19/2020 03:33 PM] (2) |
| Feb 14, 2020 | 32 | ORDER filed granting motion to expedite [8] to the extent that Takeda's opening brief is due no later than February 19, 2020; Mylan's response brief is due no later than March 11, 2020; Takeda's reply brief is due no later than March 18, 2020; and the joint appendix is due no later than March 23, 2020. The appeal will be placed on the June 2020 oral argument calendar. (Per Curiam). Service as of this date by the Clerk of Court. [671300] [LMS] [Entered: 02/14/2020 09:17 AM] (2) |
| Feb 12, 2020 | 31 | Notice of Correction to Doc No. [29], [30] from Amici Curiae Hikma Pharmaceuticals USA, Inc. and Hikma Pharmaceuticals International Limited. Service: 02/12/2020 by email. [670923] [20-1407] [Charles Klein] [Entered: 02/12/2020 07:45 PM] (5) |
| Feb 12, 2020 | 30 | REPLY of Hikma Pharmaceuticals USA, Inc. and Hikma Pharmaceuticals International Limited to response [27]. Service: 02/12/2020 by email. [670863] [20-1407] [Charles Klein] [Entered: 02/12/2020 03:59 PM] (13) |
| Feb 12, 2020 | 29 | MODIFIED ENTRY: REPLY of Movants Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA Inc. to response [27]. Service: 02/12/2020 by email. [670826]--[Edited 02/13/2020 by JCA - Reason: to correct filing event] [Charles Klein] [Entered: 02/12/2020 03:15 PM] (13) |
| Feb 11, 2020 | 28 | Docketing Statement for the Appellee Mylan Pharmaceuticals Inc.. Service: 02/11/2020 by email. [670343] [20-1407] [Michael Sommer] [Entered: 02/11/2020 03:04 PM] (4) |
| Feb 10, 2020 | 27 | RESPONSE of Appellee Mylan Pharmaceuticals Inc. to the motion for leave to file an amicus curiae brief [18]. Service: 02/10/2020 by email. [670007] [20-1407] [Michael Sommer] [Entered: 02/10/2020 09:54 PM] (27) |
| Feb 7, 2020 | 26 | REPLY of Appellant Takeda Pharmaceuticals U.S.A., Inc. to response [21]. Service: 02/07/2020 by email. [669570] [20-1407] [Edgar Haug] [Entered: 02/07/2020 07:57 PM] (31) |
| Feb 5, 2020 | 25 | Entry of appearance for Shyamkrishna Palaiyanur as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 02/05/2020 by email. [668701] [20-1407] [Shyamkrishna Palaiyanur] [Entered: 02/05/2020 03:18 PM] (2) |
| Feb 5, 2020 | 24 | Entry of appearance for Sheryl Shapiro Bassin as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 02/05/2020 by email. [668700] [20-1407] [Sheryl Shapiro Bassin] [Entered: 02/05/2020 03:15 PM] (2) |
| Feb 5, 2020 | 23 | Entry of appearance for Jessica L. Margolis as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 02/05/2020 by email. [668610] [20-1407] [Jessica Margolis] [Entered: 02/05/2020 12:06 PM] (2) |
| Feb 4, 2020 | 22 | Certificate of Interest for Appellee Mylan Pharmaceuticals Inc.. Service: 02/04/2020 by email. [668460] [20-1407] [Michael Sommer] [Entered: 02/04/2020 10:52 PM] (3) |
| Feb 4, 2020 | 21 | RESPONSE of Appellee Mylan Pharmaceuticals Inc. to the motion for temporary injunction pending appeal [6] filed by Appellant Takeda Pharmaceuticals U.S.A., Inc.. Service: 02/04/2020 by email. [668459] [20-1407] [Michael Sommer] [Entered: 02/04/2020 10:48 PM] (47) |
| Feb 3, 2020 | 20 | RESPONSE of Appellee Mylan Pharmaceuticals Inc. to the motion to expedite briefing [8] filed by Appellant Takeda Pharmaceuticals U.S.A., Inc., motion to expedite hearing [8] filed by Appellant Takeda Pharmaceuticals U.S.A., Inc.. Service: 02/03/2020 by email. [668130] [20-1407] [Michael Sommer] [Entered: 02/03/2020 08:05 PM] (7) |
| Feb 3, 2020 | 19 | ORDER directing Mylan Pharmaceuticals Inc. to file any opposition to the motion [18] no later than five days from the date of issuance of this order. Any reply is due no later than two days from the filing of the response. Service as of this date by the Clerk of Court. [668090] [NL] [Entered: 02/03/2020 04:59 PM] (2) |
| Feb 3, 2020 | 18 | MOTION of Hikma Pharmaceuticals USA, Inc. and Hikma Pharmaceuticals International Limited for leave to file an amicus curiae brief [Consent: opposed]. Service: 02/03/2020 by email. [668017] [20-1407] [Charles Klein] [Entered: 02/03/2020 03:03 PM] (29) |
| Feb 3, 2020 | 17 | Entry of appearance for Dan H. Hoang as of counsel for Hikma Pharmaceuticals USA, Inc. and Hikma Pharmaceuticals International Limited. Service: 02/03/2020 by email. [668007] [20-1407] [Dan Hoang] [Entered: 02/03/2020 02:55 PM] (2) |
| Feb 3, 2020 | 16 | Entry of appearance for Charles B. Klein as principal counsel for Hikma Pharmaceuticals USA, Inc. and Hikma Pharmaceuticals International Limited. Service: 02/03/2020 by email. [668001] [20-1407] [Charles Klein] [Entered: 02/03/2020 02:51 PM] (2) |
| Jan 29, 2020 | 15 | ORDER directing Mylan Pharmaceuticals Inc. to respond to the motion to expedite [8] no later than five days from the date of filing of this order. Any reply in support of the motion is due no later than one day thereafter. Service as of this date by the Clerk of Court. [667083] [LMS] [Entered: 01/29/2020 04:43 PM] (2) |
| Jan 29, 2020 | 14 | ORDER filed directing Mylan to respond to the motion for an injunction pending appeal [6] no later than seven days from the date of filing of this order. Any reply in support of the motion is due no later than three days thereafter. Takeda's request for an interim injunction is granted to the extent that the district court's order that Mylan “maintain the status quo” shall remain in effect pending the court's consideration of Takeda's request for an injunction pending appeal. Service as of this date by the Clerk of Court. [667077] [LMS] [Entered: 01/29/2020 04:24 PM] (2) |
| Jan 29, 2020 | 13 | Letter from Appellant Takeda Pharmaceuticals U.S.A., Inc. re response to letter concerning Mylan's opposition to an interim temporary injunction during the pendency of Takeda's Emergency Motion for an Injunction Pending Appeal. Service: 01/29/2020 by email. [667046] [20-1407] [Porter Fleming] [Entered: 01/29/2020 03:36 PM] (1) |
| Jan 29, 2020 | 12 | Letter from Appellee Mylan Pharmaceuticals Inc. re opposition to any interim temporary injunction during the pendency of the Emergency Motion of Plaintiff-Appellant Takeda Pharmaceuticals U.S.A., Inc. for an Injunction Pending Appeal. Service: 01/29/2020 by email. [667010] [20-1407] [Michael Sommer] [Entered: 01/29/2020 02:45 PM] (1) |
| Jan 29, 2020 | 11 | Entry of appearance for Michael S. Sommer as principal counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 01/29/2020 by email. [667007] [20-1407] [Michael Sommer] [Entered: 01/29/2020 02:40 PM] (1) |
| Jan 29, 2020 | 10 | Docketing Statement for the Appellant Takeda Pharmaceuticals U.S.A., Inc.. Service: 01/29/2020 by email. [666849] [20-1407] [Edgar Haug] [Entered: 01/29/2020 11:08 AM] (4) |
| Jan 29, 2020 | 9 | Certificate of Interest for Appellant Takeda Pharmaceuticals U.S.A., Inc.. Service: 01/29/2020 by email. [666845] [20-1407] [Edgar Haug] [Entered: 01/29/2020 11:07 AM] (3) |
| Jan 28, 2020 | 8 | MOTION of Appellant Takeda Pharmaceuticals U.S.A., Inc. to expedite briefing schedule, to expedite hearing [Consent: not addressed]. Service: 01/28/2020 by email. [666718] [20-1407] [Edgar Haug] [Entered: 01/28/2020 10:22 PM] (13) |
| Jan 28, 2020 | 7 | Confidential Exhibit 2 to Emergency Motion for Injunction Pending Appeal filed by Appellant Takeda Pharmaceuticals U.S.A., Inc. corresponding to Doc. No. [6]. Service: 01/28/2020 by email. [666714] [20-1407] [Edgar Haug] [Entered: 01/28/2020 10:00 PM] (0) |
| Jan 28, 2020 | 6 | MOTION of Appellant Takeda Pharmaceuticals U.S.A., Inc. for temporary injunction [Consent: opposed]. Service: 01/28/2020 by email. [666711] [20-1407] [Edgar Haug] [Entered: 01/28/2020 09:54 PM] (43) |
| Jan 28, 2020 | 5 | Entry of appearance for Camille Y. Turner as of counsel for Appellant Takeda Pharmaceuticals U.S.A., Inc.. Service: 01/28/2020 by email. [666697] [20-1407] [Jonathan Herstoff] [Entered: 01/28/2020 06:57 PM] (2) |
| Jan 28, 2020 | 4 | Entry of appearance for Jonathan A. Herstoff as of counsel for Appellant Takeda Pharmaceuticals U.S.A., Inc.. Service: 01/28/2020 by email. [666696] [20-1407] [Jonathan Herstoff] [Entered: 01/28/2020 06:55 PM] (2) |
| Jan 28, 2020 | 3 | Entry of appearance for Porter F. Fleming as of counsel for Appellant Takeda Pharmaceuticals U.S.A., Inc.. Service: 01/28/2020 by email. [666695] [20-1407] [Porter Fleming] [Entered: 01/28/2020 06:52 PM] (2) |
| Jan 28, 2020 | 2 | Entry of appearance for Edgar H. Haug as principal counsel for Appellant Takeda Pharmaceuticals U.S.A., Inc.. Service: 01/28/2020 by email. [666694] [20-1407] [Edgar Haug] [Entered: 01/28/2020 06:49 PM] (2) |
| Jan 28, 2020 | 1 | Appeal docketed. Received: 01/27/2020. [666619]Entry of Appearance due 02/11/2020. Certificate of Interest is due on 02/11/2020. Docketing Statement due 02/11/2020. Appellant's brief is due 03/30/2020. [TAM] [Entered: 01/28/2020 03:41 PM] (23) |
